Cholesterol metabolism: a positive target to revoke the function of exhausted CAR-NK cells in tumor microenvironment.
作者信息
Liu Jingfeng
机构信息
Shenzhen Key Laboratory of Immunity and Inflammatory Diseases, Peking University Shenzhen Hospital, Shenzhen, China.
Department of Rheumatism and Immunology, Peking University Shenzhen Hospital, Shenzhen, China.
出版信息
Front Pharmacol. 2024 Sep 16;15:1440869. doi: 10.3389/fphar.2024.1440869. eCollection 2024.
Abstract
摘要
相似文献
1
Cholesterol metabolism: a positive target to revoke the function of exhausted CAR-NK cells in tumor microenvironment.胆固醇代谢：恢复肿瘤微环境中耗竭的嵌合抗原受体自然杀伤细胞功能的积极靶点。
Front Pharmacol. 2024 Sep 16;15:1440869. doi: 10.3389/fphar.2024.1440869. eCollection 2024.
2
Strong capacity of differentiated PD-L1 CAR-modified UCB-CD34 cells and PD-L1 CAR-modified UCB-CD34-derived NK cells in killing target cells and restoration of the anti-tumor function of PD-1-high exhausted T Cells.具有强大分化能力的 PD-L1 CAR 修饰的 UCB-CD34 细胞和 PD-L1 CAR 修饰的 UCB-CD34 衍生 NK 细胞，能够杀伤靶细胞，并恢复 PD-1 高表达耗竭 T 细胞的抗肿瘤功能。
Stem Cell Res Ther. 2024 Aug 13;15(1):257. doi: 10.1186/s13287-024-03871-5.
3
Chimeric antigen receptor-natural killer cell therapy: current advancements and strategies to overcome challenges.嵌合抗原受体自然杀伤细胞疗法：当前进展及克服挑战的策略。
Front Immunol. 2024 Apr 25;15:1384039. doi: 10.3389/fimmu.2024.1384039. eCollection 2024.
4
NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors.嵌合激活受体表达的自然杀伤细胞消除髓系抑制细胞并挽救针对实体瘤的嵌合抗原受体 T 细胞活性受损。
Cancer Immunol Res. 2019 Mar;7(3):363-375. doi: 10.1158/2326-6066.CIR-18-0572. Epub 2019 Jan 16.
5
Circumventing resistance within the Ewing sarcoma microenvironment by combinatorial innate immunotherapy.通过组合性先天免疫疗法绕过尤文肉瘤微环境中的耐药性。
J Immunother Cancer. 2024 Sep 12;12(9):e009726. doi: 10.1136/jitc-2024-009726.
6
In Vitro Evaluation of CD276-CAR NK-92 Functionality, Migration and Invasion Potential in the Presence of Immune Inhibitory Factors of the Tumor Microenvironment.在肿瘤微环境免疫抑制因子存在的情况下，评估 CD276-CAR NK-92 功能、迁移和侵袭潜能的体外研究。
Cells. 2021 Apr 26;10(5):1020. doi: 10.3390/cells10051020.
7
Challenges in αCD38-chimeric antigen receptor (CAR)-expressing natural killer (NK) cell-based immunotherapy in multiple myeloma: Harnessing the CD38dim phenotype of cytokine-stimulated NK cells as a strategy to prevent fratricide.嵌合抗原受体（CAR）表达的自然杀伤（NK）细胞免疫疗法在多发性骨髓瘤中面临的挑战：利用细胞因子刺激的 NK 细胞的 CD38dim 表型作为防止自相残杀的策略。
Cytotherapy. 2023 Jul;25(7):763-772. doi: 10.1016/j.jcyt.2023.03.006. Epub 2023 Apr 11.
8
Chimeric antigen receptor natural killer cells: a promising antitumor immunotherapy.嵌合抗原受体自然杀伤细胞：一种有前景的抗肿瘤免疫疗法。
MedComm (2020). 2023 Dec 1;4(6):e422. doi: 10.1002/mco2.422. eCollection 2023 Dec.
9
Overcoming tumor resistance mechanisms in CAR-NK cell therapy.克服 CAR-NK 细胞治疗中的肿瘤耐药机制。
Front Immunol. 2022 Aug 3;13:953849. doi: 10.3389/fimmu.2022.953849. eCollection 2022.
10
Next-Generation CEA-CAR-NK-92 Cells against Solid Tumors: Overcoming Tumor Microenvironment Challenges in Colorectal Cancer.下一代抗实体瘤的CEA-CAR-NK-92细胞：克服结直肠癌中的肿瘤微环境挑战
Cancers (Basel). 2024 Jan 16;16(2):388. doi: 10.3390/cancers16020388.
引用本文的文献
1
Lipid Metabolism Reprogramming in Cancer: Insights into Tumor Cells and Immune Cells Within the Tumor Microenvironment.癌症中的脂质代谢重编程：对肿瘤微环境中肿瘤细胞和免疫细胞的见解
Biomedicines. 2025 Aug 4;13(8):1895. doi: 10.3390/biomedicines13081895.
2
Spatial genomics reveals cholesterol metabolism as a key factor in colorectal cancer immunotherapy resistance.空间基因组学揭示胆固醇代谢是结直肠癌免疫治疗耐药的关键因素。
Front Oncol. 2025 Mar 18;15:1549237. doi: 10.3389/fonc.2025.1549237. eCollection 2025.
本文引用的文献
1
MEF2C regulates NK cell effector functions through control of lipid metabolism.MEF2C通过控制脂质代谢来调节自然杀伤细胞的效应功能。
Nat Immunol. 2024 May;25(5):778-789. doi: 10.1038/s41590-024-01811-2. Epub 2024 Apr 8.
2
How chemokines organize the tumour microenvironment.趋化因子如何组织肿瘤微环境。
Nat Rev Cancer. 2024 Jan;24(1):28-50. doi: 10.1038/s41568-023-00635-w. Epub 2023 Dec 8.
3
CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances.实体瘤治疗时代的嵌合抗原受体细胞治疗：当前的挑战和新出现的治疗进展。
Mol Cancer. 2023 Jan 30;22(1):20. doi: 10.1186/s12943-023-01723-z.
4
Synthetic cytokine circuits that drive T cells into immune-excluded tumors.合成细胞因子电路将 T 细胞驱入免疫排斥肿瘤中。
Science. 2022 Dec 16;378(6625):eaba1624. doi: 10.1126/science.aba1624.
5
CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy.嵌合抗原受体（CAR）在癌症免疫疗法中的竞赛：从 CAR T、CAR NK 到 CAR 巨噬细胞疗法。
J Exp Clin Cancer Res. 2022 Mar 31;41(1):119. doi: 10.1186/s13046-022-02327-z.
6
CRISPR screens identify cholesterol biosynthesis as a therapeutic target on stemness and drug resistance of colon cancer.CRISPR 筛选鉴定胆固醇生物合成作为结肠癌干性和耐药性的治疗靶点。
Oncogene. 2021 Dec;40(48):6601-6613. doi: 10.1038/s41388-021-01882-7. Epub 2021 Oct 7.
7
Increased lipid metabolism impairs NK cell function and mediates adaptation to the lymphoma environment.脂质代谢增加会损害 NK 细胞功能，并介导对淋巴瘤微环境的适应。
Blood. 2020 Dec 24;136(26):3004-3017. doi: 10.1182/blood.2020005602.
8
Cholesterol metabolism in cancer: mechanisms and therapeutic opportunities.癌症中的胆固醇代谢：机制与治疗机遇。
Nat Metab. 2020 Feb;2(2):132-141. doi: 10.1038/s42255-020-0174-0. Epub 2020 Feb 10.
9
NK Cell Metabolism and Tumor Microenvironment.自然杀伤细胞代谢与肿瘤微环境。
Front Immunol. 2019 Sep 24;10:2278. doi: 10.3389/fimmu.2019.02278. eCollection 2019.
10
Myeloid immunosuppression and immune checkpoints in the tumor microenvironment.肿瘤微环境中的髓系免疫抑制和免疫检查点。
Cell Mol Immunol. 2020 Jan;17(1):1-12. doi: 10.1038/s41423-019-0306-1. Epub 2019 Oct 14.
Zotero 插件